UK NSC recommends targeted prostate cancer screening for men with BRCA2 variants
The UK National Screening Committee has endorsed a risk-stratified approach to prostate cancer screening, focusing on men who carry a BRCA2 pathogenic variant and have a relevant family history of cancer.
The UK National Screening Committee (UK NSC) has formally recommended targeted prostate cancer screening for men who carry a pathogenic BRCA2 variant and have a family history of BRCA2-linked cancers. The announcement, reported by Cancer Research UK, marks a substantive step towards risk-stratified, rather than population-wide, prostate cancer screening in the UK.
BRCA2 pathogenic variants are well established as significantly increasing prostate cancer risk, particularly for aggressive, early-onset disease. The UK NSC's position reflects a growing body of evidence — including data from the IMPACT study and related work — that men in this group may benefit from earlier detection opportunities compared with the general population.
For genetic counsellors and genetics services, the recommendation has direct implications for cascade testing conversations and family-history assessments: men identified as BRCA2 carriers through hereditary cancer pathways may now be directed towards relevant clinical guidance. Published guidance from the UK NSC notes that targeted screening may be considered in this group; referral decisions remain a matter for individual clinicians in accordance with NHS protocols.
The recommendation does not apply to men with BRCA1 variants or to the general male population. The UK NSC continues to advise against population-wide PSA screening for prostate cancer. Full details of the recommendation and the supporting evidence review are available on the UK NSC website.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
The UK National Screening Committee — the body that advises the NHS on screening programmes — has recommended that men who carry a specific gene change called BRCA2, and who also have a family history of certain cancers, should be offered targeted prostate cancer screening. BRCA2 is a gene that, when altered, can raise the risk of several cancers, including prostate cancer in men.
This recommendation does not apply to all men, and it is separate from any decision about general prostate cancer screening for the wider population. Researchers and clinicians say the move represents an important step towards matching screening to individual genetic risk.
If you or a family member has been told about a BRCA2 gene change through a genetics service, a genetic counsellor or GP will be best placed to explain what this recommendation means for your situation.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Cancer Research UK · 2026-05-28UK NSC recommends targeted prostate cancer screening